Yeh CP, Huang YW, Tsai TF.
Issues - Settembre 2022
Yeh CP, Huang YW, Tsai TF.
Ghalandari N, Crijns HJMJ, Bergman JEH, et al.
Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics: a retrospective comparative study in EudraVigilance
Br J Clin Pharmacol. 2022 Jul 27. Online ahead of printNorden A, Moon JY, Javadi SS, et al.
Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1171-1177Kara Polat A, Alpsoy E, Kalkan G, et al.
Sociodemographic, clinical, laboratory, treatment and prognostic characteristics of 156 generalized pustular psoriasis patients in Turkey: a multicentre case series
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1256-1265Kwiecinska P, Grygier B, Morytko A, et al.
Secretory leukocyte protease inhibitor regulates nerve reflex-mediated skin barrier function in psoriasis
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1266-1274Reich K, Iversen L, Puig L, et al.
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1275-1283Loft N, Egeberg A, Rasmussen MK, et al.
Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study
J Eur Acad Dermatol Venereol. 2022 Aug;36(8):1284-1291Tehlirian C, Singh RSP, Pradhan V, et al.
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
J Am Acad Dermatol. 2022 Aug;87(2):333-342Shen M, Xiao Y, Jing D, et al.
Associations of combined lifestyle and genetic risks with incident psoriasis: A prospective cohort study among UK Biobank participants of European ancestry
J Am Acad Dermatol. 2022 Aug;87(2):343-350Gordon KB, Langley RG, Warren RB, et al.
Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials
JAMA Dermatol. 2022 Jul 1;158(7):735-744Enevold C, Loft N, Bregnhøj A, et al.
Circulating brodalumab levels and therapy outcomes in patients with psoriasis treated with brodalumab: a case series
JAMA Dermatol. 2022 Jul 1;158(7):762-769Drerup KA, Seemann C, Gerdes S, et al.
Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients
Dermatology. 2022;238(4):615-619Kokolakis G, Vadstrup K, Hansen JB, et al.